A citation-based method for searching scientific literature


List of co-cited articles
1331 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
40



Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
23

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
23


Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
563
17


Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
16

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
417
15


A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
14

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
207
14

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
129
13

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.
AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao,[...]. BMC Psychiatry 2014
66
19

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
46
26



Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
227
11


Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
147
10

Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
Jerri M Rook, Zixiu Xiang, Xiaohui Lv, Ayan Ghoshal, Jonathan W Dickerson, Thomas M Bridges, Kari A Johnson, Daniel J Foster, Karen J Gregory, Paige N Vinson,[...]. Neuron 2015
84
11

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
10

Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
Scott A Schobel, Nashid H Chaudhury, Usman A Khan, Beatriz Paniagua, Martin A Styner, Iris Asllani, Benjamin P Inbar, Cheryl M Corcoran, Jeffrey A Lieberman, Holly Moore,[...]. Neuron 2013
317
10


AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
46
21



Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.
Matthew J Fell, David L McKinzie, James A Monn, Kjell A Svensson. Neuropharmacology 2012
72
12

Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
82
10

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
127
9

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
John H Krystal, D Cyril D'Souza, Daniel Mathalon, Edward Perry, Aysenil Belger, Ralph Hoffman. Psychopharmacology (Berl) 2003
402
9

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
76
11


Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
9

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.
John E Lisman, Joseph T Coyle, Robert W Green, Daniel C Javitt, Francine M Benes, Stephan Heckers, Anthony A Grace. Trends Neurosci 2008
715
9

mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks.
Lu E Jin, Min Wang, Veronica C Galvin, Taber C Lightbourne, Peter Jeffrey Conn, Amy F T Arnsten, Constantinos D Paspalas. Cereb Cortex 2018
51
17

Effects of ketamine in normal and schizophrenic volunteers.
A C Lahti, M A Weiler, B A Tamara Michaelidis, A Parwani, C A Tamminga. Neuropsychopharmacology 2001
450
9


Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
464
8


Glutamate receptor ion channels: structure, regulation, and function.
Stephen F Traynelis, Lonnie P Wollmuth, Chris J McBain, Frank S Menniti, Katie M Vance, Kevin K Ogden, Kasper B Hansen, Hongjie Yuan, Scott J Myers, Ray Dingledine. Pharmacol Rev 2010
8

Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus.
R Shigemoto, A Kinoshita, E Wada, S Nomura, H Ohishi, M Takada, P J Flor, A Neki, T Abe, S Nakanishi,[...]. J Neurosci 1997
848
8

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
Meng-Lin Li, Xi-Quan Hu, Feng Li, Wen-Jun Gao. Prog Neuropsychopharmacol Biol Psychiatry 2015
40
20

Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Sophie Parmentier-Batteur, Peter H Hutson, Karsten Menzel, Jason M Uslaner, Britta A Mattson, Julie A O'Brien, Brian C Magliaro, Thomas Forest, Craig A Stump, Robert M Tynebor,[...]. Neuropharmacology 2014
68
11

A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors.
Etienne Doumazane, Pauline Scholler, Jurriaan M Zwier, Eric Trinquet, Philippe Rondard, Jean-Philippe Pin. FASEB J 2011
199
8

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Feng Liu, Steve Grauer, Cody Kelley, Rachel Navarra, Radka Graf, Guoming Zhang, Peter J Atkinson, Michael Popiolek, Caitlin Wantuch, Xavier Khawaja,[...]. J Pharmacol Exp Ther 2008
161
8

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
297
8

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
8

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.
Adam G Walker, Cody J Wenthur, Zixiu Xiang, Jerri M Rook, Kyle A Emmitte, Colleen M Niswender, Craig W Lindsley, P Jeffrey Conn. Proc Natl Acad Sci U S A 2015
65
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.